Supp. Figure 3 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers
Chloé Prunier(Inserm), Laurence Lafanéchère(Centre National de la Recherche Scientifique), Reuben Kapur(Indiana University School of Medicine), Christos J. Petropoulos(IGM Biosciences (United States)), Julien Vollaire(Inserm), Christopher Montemagno(Scientific Centre of Monaco), Jacco van Rheenen(The Netherlands Cancer Institute), Olivier Destaing(Centre National de la Recherche Scientifique), Leanne de Koning(Université Paris Sciences et Lettres), Véronique Josserand(Centre National de la Recherche Scientifique), Renaud Prudent(BIOASTER), Marc Billaud(Université Claude Bernard Lyon 1), Corinne Albigès‐Rizo(Centre National de la Recherche Scientifique), Amandine Hurbin(Agir Pour les Maladies Chroniques), Evelyne Beerling(Heidelberg University), Pascale A. Cohen(Lyon 1 Université), Jean‐Luc Coll(Unknown)
Cited by 0
Related Papers
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
|Proceedings of the National Academy of Sciences|2003|1.2k
Collagen-based cell migration models in vitro and in vivo
|Seminars in Cell and Developmental Biology|2009|647
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410
Integrins β1 and β3 exhibit distinct dynamic nanoscale organizations inside focal adhesions
|Nature Cell Biology|2012|390
Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
|The Journal of Infectious Diseases|2021|332